Latest News and Press Releases

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

CytoSorbents Strengthens Balance Sheet by $11.25M in Unrestricted Cash through Oversubscribed Shareholder Rights Offering and Satisfied Debt Covenant

CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai, United Arab Emirates, a Gateway to the Middle East and Africa

CytoSorbents' Preliminary Unaudited Q4 2024 Product Revenue Increased 22-25% From A Year Ago With Product Gross Margins Of ~70%

CytoSorbents Rights Offering Begins. Eligible Stockholders are Being Distributed a Dividend of Subscription Rights Based on Shares of CTSO Held.

CytoSorbents Announces Rights Offering Exclusive to Stockholders Who Hold or Have Bought CTSO Common Stock by Market Close on Friday, December 13, 2024

CytoSorbents to Participate in the Piper Sandler 36th Annual Healthcare Conference. Management holding one-on-one meetings with investors

PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

CytoSorbents submits DrugSorb-ATR Medical Device License Application to Health Canada following MDSAP Certification. Expects regulatory decision in 2025

FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected